Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

Por Han, Kelong, Jin, Jin, Maia, Mauricio, Lowe, John, Sersch, Martina A., Allison, David E.
Publicado em 2014

Population pharmacokinetics of bevacizumab in cancer patients with external validation

Por Han, Kelong, Peyret, Thomas, Marchand, Mathilde, Quartino, Angelica, Gosselin, Nathalie H., Girish, Sandhya, Allison, David E., Jin, Jin
Publicado no Cancer Chemother Pharmacol (2016)

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation

Por Han, Kelong, Peyret, Thomas, Quartino, Angelica, Gosselin, Nathalie H., Gururangan, Sridharan, Casanova, Michela, Merks, Johannes H. M., Massimino, Maura, Grill, Jacques, Daw, Najat C., Navid, Fariba, Jin, Jin, Allison, David E.
Publicado no Br J Clin Pharmacol (2015)

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

Por Khawli, Leslie A, Goswami, Sirj, Hutchinson, Ryan, Kwong, Zephania W, Yang, Jihong, Wang, Xiangdan, Yao, Zhenling, Sreedhara, Alavattam, Cano, Tony, Tesar, Devin, Nijem, Ihsan, Allison, David E, Wong, Pin Yee, Kao, Yung-Hsiang, Quan, Cynthia, Joshi, Amita, Harris, Reed J, Motchnik, Paul
Publicado em 2010